RNA therapeutics have emerged as a new modality for treating life threatening conditions and combating serious infections. Acting as the ‘software’ that programmes the body’s own cells to manufacture proteins or antigens, to which the immune system responds to generate immunity.
First-generation mRNA vaccines have been successfully used to combat the COVID-19 pandemic.
The first-generation mRNA vaccines have been successfully used to combat the COVID-19 pandemic. However, the impact and reach of these vaccines and therapeutics may be limited by tolerability, cost of goods and stability. Modulating the immune response and better matching the delivery modality can improve tolerability, enable lower doses, minimize cost of goods and improve stability.
